Best practices for the Multidisciplinary Management of NHL using Antibody Therapeutics

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
In the phase 3 POLARIX study, the role of polatuzumab vedotin was supported in the following subset of patients: 
Which statement regarding the findings of the phase 2 LOTIS-2 trial investigating loncastuximab tesierine in patients with R/R DLBCL is true?
Alexander is a 53-year-old man with primary refractory non-GCB DLBCL who was previously treated with R-CHOP, followed by axi-cel. He now presents with worsening lymphadenopathy. You confirm relapse with excisional biopsy. What is the next best step for this patient? 
Martin is a 64-year-old male who has primary refractory advanced stage GCB DLBCL.   He has previously been treated with R-DA-EPOCH, followed by Pola-BR and axi-cel. You determine now that he may be a viable candidate for a bispecific antibody. When counseling the patient about adverse events related to treatment with this class of agents, your discussion should include which of the following? 
Powered by QuestionPro